Biomotion Sciences. Ordinary Shares SLXN 深 滬
已收盤 08-01 16:00:00 美东时间
9.28
-5.660
-37.88%
華盛通- 最 高11.10
- 今 開11.10
- 成交量 36.02万股
- 最 低 7.82
- 昨 收 14.94
- 總市值 8066.55万
- 52周最高 627.75
- 市盈率 靜 --
- 換手率 4.14%
- 52周最低 7.82
- 委 比 -25.93%
- 總股本 869.24万
- 歷史最高 627.75
- 量 比 0.70
- 振 幅 21.95%
- 歷史最低 7.82
- 每 手 1
- 風險率 1.34%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Silexion Therapeutics Enters Inducement Offer Agreement
Silexion Therapeutics ( ($SLXN) ) just unveiled an announcement. On July 31, 20...
08-02 00:48
Why Is Silexion Therapeutics Stock Trading Higher On Thursday?
Silexion's SIL204 showed strong KRAS-targeted inhibition across pancreatic, colorectal, and lung cancer cells, supporting its advancement to clinical trials.
08-01 03:14
Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds
Silexion Therapeutics Corp. announced the exercise of warrants to purchase up to 152,106 ordinary shares at $11.57 per share, generating approximately $1.8 million in gross proceeds. The company will issue new unregistered warrants for up to 304,212 shares with an exercise price of $11.32, exercisable upon shareholder approval of increased authorized shares. H.C. Wainwright & Co. acted as the placement agent. Proceeds will support general corpora...
08-01 00:00
Silexion Continues To Prepare For Initiation Of Phase 2/3 Clinical Trial In Q2 2026 To Investigate SIL204 For Treatment Of KRAS-Driven Solid Tumor Cancers
Silexion continues to prepare for the initiation of a Phase 2/3 clinical trial in Q2 2026 to investigate SIL204 for the treatment of KRAS-driven solid tumor cancers, leveraging both intratumoral and systemic delivery
07-31 21:58
Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation
Silexion Therapeutics announced new preclinical data showing SIL204 achieves up to 97% inhibition in pancreatic cancer cells and nearly 90% in colorectal cancer cells. Notably, SIL204 demonstrated efficacy against the KRAS Q61H mutation for the first time, expanding its potential as a pan-KRAS therapeutic. The company plans to initiate a Phase 2/3 clinical trial in Q2 2026.
07-31 13:55
Silexion Therapeutics Completes Reverse Share Split
The latest announcement is out from Silexion Therapeutics ( ($SLXN) ). Silexion...
07-29 21:27
Silexion Therapeutics Announces 1-for-15 Reverse Stock Split, Will Begin Trading On A Split-Adjusted Basis On July 29, 2025
Silexion Therapeutics Corp. (NASDAQ:SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-15 reverse
07-16 20:45
Silexion Therapeutics Announces Preclinical Data Demonstrating SIL204 Efficacy In Human Lung Cancer Cell Lines
The study revealed significant dose-dependent inhibition in lung cancer cells harboring KRAS G12D mutations, with notable efficacy, highlighting SIL204's potential as a versatile therapeutic for lung cancer. The results
07-09 20:32
Silexion Therapeutics Stays Listed on Nasdaq After Appeal
Silexion Therapeutics ( ($SLXN) ) has issued an update. On July 7, 2025, Silexi...
07-08 21:57
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Lyra Therapeutics (NASDAQ:LYRA) shares moved upwards by 463.3% to $27....
06-02 20:07
